Sales declined to $1.7m due to delayed rollouts, but FY2026 is projected to rebound to $2.8m with resumed programs and new market entries. China remains the core market, while strategic alliances and WHO validation support global expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.